Related Experiment Video
Updated: Jul 24, 2025
07:45
Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
Published on: January 26, 2024
2.0K
Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFNγ
Xiaojing Xu1, Cheng Yi2, Tianyun Feng2
1College of Basic Medicine and Biological Sciences, Medical Department, Soochow University, Suzhou 215123, Jiangsu, China.
Clinical Immunology (Orlando, Fla.)
|July 5, 2023
Summary
A novel lipid-glycoadjuvant (LCpG) enhances cancer vaccine efficacy by improving lymph node targeting and boosting tumor-specific T cell responses. This adjuvant effectively controls tumors, reduces metastasis, and establishes long-term immunity.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- Effective cancer immunotherapy requires inducing tumor-specific T cell responses and overcoming suppressive tumor microenvironments.
- CpG oligonucleotides (ODN), Toll-like receptor 9 agonists, are used as vaccine adjuvants but can be improved for targeting.
- Novel adjuvant strategies are needed to enhance lymph node delivery and T cell activation for improved cancer treatment.
Purpose of the Study:
- To develop and evaluate a novel lipid-glycopolymer-modified CpG adjuvant (LCpG) for enhanced lymph node targeting and immunotherapy.
- To investigate the anti-tumor effects of LCpG in a melanoma model, focusing on T cell responses and tumor microenvironment modulation.
- To assess the combination therapy of LCpG with anti-PD-1 immunotherapy for synergistic anti-tumor efficacy.
Main Methods:
- LCpG was synthesized by modifying CpG with lipid and glycopolymers using photo-induced RAFT polymerization and click chemistry.
- Immunotherapy efficacy was tested in a melanoma mouse model using OVA protein as a model antigen.
- Flow cytometry, cytotoxicity assays, cell depletion, cytokine neutralization, and adoptive transfer were used to analyze T cell responses and tumor microenvironment changes.
Main Results:
- LCpG demonstrated rapid transport and prolonged retention in lymphoid nodes compared to unmodified CpG.
- LCpG controlled primary tumor growth and metastasis, establishing long-term memory and activating tumor-specific Tc1 responses.
- LCpG promoted CTL infiltration, M1 macrophage polarization, and Treg regulation in the tumor microenvironment, dependent on CTL-derived IFN-γ.
- Combination therapy with anti-PD-1 significantly enhanced the anti-tumor efficacy of LCpG.
Conclusions:
- LCpG is a promising adjuvant for cancer vaccines, augmenting tumor-specific Tc1 activity and modulating the tumor microenvironment.
- The anti-tumor activity of LCpG is mediated by CTL-derived IFN-γ and is significantly enhanced when combined with anti-PD-1 immunotherapy.
- LCpG represents a novel strategy for improving cancer immunotherapy by enhancing vaccine adjuvant properties and immune cell activation.
Related Concept Videos
01:27Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
02:17The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K